House com­mit­tee holds hear­ing to iden­ti­fy root caus­es of re­cent drug short­ages

A law­mak­er de­scribed the eco­nom­ics of gener­ic drug man­u­fac­tur­ing as “un­ap­peal­ing” to man­u­fac­tur­ers and said that may be one rea­son for the drug short­age cri­sis in the US dur­ing a House hear­ing on Thurs­day.

Drug short­ages in­creased by al­most 30% be­tween 2021 and 2022, with the ASHP record­ing 247 ac­tive short­ages, ac­cord­ing to Chair­man Rep. Mor­gan Grif­fith’s (R-VA) re­marks dur­ing the En­er­gy and Com­merce Com­mit­tee’s Over­sight and In­ves­ti­ga­tions Sub­com­mit­tee hear­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER